Xeljanz

Xeljanz (tofacitinib), prescribed to treat moderate to severe rheumatoid arthritis and active psoriatic arthritis in adults, blocks the activity of enzymes that affect immune system function. The drug is also used to treat adults with moderate to severe ulcerative colitis in patients for whom other medications have failed. Safety clinical trials indicated an increased risk of clots in lungs and deaths associated with tofacitinib. In July 2019, the FDA approved a Boxed Warning about increased risk of blood clots and death with higher doses of the medication.